SCHEMBL364754

SCHEMBL364754

COc1cc(C(N)=O)ccc1Oc1ccc(Cl)c(Cl)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 4/20 0.64
HTR2A P28223 3/20 0.64
KCNH2 Q12809 2/20 0.64
CHEK2 O96017 4/20 0.55
MAPK1 P28482 1/20 0.54
LMNA P02545 2/20 0.51
GAA P10253 2/20 0.50
TTR P02766 2/20 0.50
CRHBP P24387 1/20 0.50
CRHR2 Q13324 1/20 0.50
ALDH1A1 P00352 1/20 0.50
SLC6A2 P23975 1/20 0.50
SLC6A3 Q01959 1/20 0.50
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C9 P11712 1/20 0.49
TSHR P16473 1/20 0.49
CYP2C19 P33261 1/20 0.49
CA1 P00915 2/20 0.47
CA2 P00918 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16319237 0.85 SLC6A4 (0.66) SLC6A4HTR2AKCNH2CHEK2ALDH1A1
SCHEMBL16319568 0.84 SLC6A4 (0.65) SLC6A4HTR2AKCNH2CHEK2LMNA
SCHEMBL11401711 0.84 PARP10 (0.67) MAPK1LMNAGAATTRALDH1A1
SCHEMBL2762379 0.80 MAPK1 (0.58) SLC6A4MAPK1LMNAGAACRHBP
SCHEMBL335681 0.80 MAPK1 (0.77) MAPK1LMNAGAAALDH1A1CYP1A2
SCHEMBL29415167 0.80 MAPK1 (0.77) MAPK1LMNAGAAALDH1A1CYP1A2
SCHEMBL680427 0.80 SCN9A (0.59) LMNA
Hydrochloric Acid SCHEMBL5154533 0.78 MAPK1 (0.74) MAPK1LMNAGAAALDH1A1CYP1A2
SCHEMBL13857896 0.78 HTR2A (0.61) SLC6A4HTR2AKCNH2MAPK1GAA
SCHEMBL1719761 0.77 MAPK1 (0.58) SLC6A4KCNH2MAPK1LMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-B1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LTD (GB) 2014-12-24 EP disclosed
EP-2593427-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN Pfizer Limited (GB) 2013-05-22 EP disclosed
WO-2012007883-A1 SULFONAMIDE DERIVATIVES AS NAV1.7 INHIBITORS FOR THE TREATMENT OF PAIN PFIZER LIMITED (GB) 2012-01-19 WO disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed
US-20120010207-A1 Chemical Compounds PFIZER LIMITED (GB) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010207-A1 Chemical Compounds SCN1A, SCN1B, SCN7A SLC6A4 597/4885HTR2A 1805/4885KCNH2 41/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.